SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast cancer ...
Detailed price information for Atossa Therapeutics Inc (ATOS-Q) from The Globe and Mail including charting and trades.
25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, ...
Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs SEATTLE, Oct. 1, 2025 ...
Virtual Meeting to be held on October 10 hosted by Craig-Hallum. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you ...
In an exclusive interview, Mark Smith, Chairman, President, and CEO of NioCorp, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's Elk Creek Project in ...
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 ...
The initial design of the EVANGELINE trial comprised 214 participants. Credit: NMK-Studio/Shutterstock.com. Atossa Therapeutics has amended its Phase II EVANGELINE study of (Z)-endoxifen for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback